17.71
13.89%
2.16
After Hours:
17.71
Septerna Inc Stock (SEPN) Latest News
Septerna (NASDAQ:SEPN) Trading Down 4.3%Time to Sell? - MarketBeat
Septerna (NASDAQ:SEPN) Sets New 52-Week LowTime to Sell? - MarketBeat
Septerna (NASDAQ:SEPN) Shares Gap UpTime to Buy? - MarketBeat
Cantor Fitzgerald Forecasts Septerna FY2025 Earnings - Defense World
Septerna (NASDAQ:SEPN) Trading 5.7% HigherShould You Buy? - MarketBeat
Brokers Set Expectations for Septerna FY2025 Earnings - MarketBeat
Modest Final Quarter Completes Shaky Biotech IPO Comeback For 2024 - News & Insights
Septerna to Introduce Groundbreaking GPCR Drug Discovery Innovations - Defense World
Septerna (NASDAQ:SEPN) Sets New 52-Week Low – Here’s What Happened - Defense World
Septerna (NASDAQ:SEPN) Sets New 12-Month LowTime to Sell? - MarketBeat
Septerna (NASDAQ:SEPN) Trading Down 8.5%Here's Why - MarketBeat
Septerna (NASDAQ: SEPN) Appoints Gil Labrucherie as Chief Financial Officer - Defense World
Third Rock-backed Maze Therapeutics reveals profit in US IPO filing - Marketscreener.com
Septerna appoints new CFO to bolster financial strategy By Investing.com - Investing.com Australia
Septerna (NASDAQ:SEPN) Shares Gap DownTime to Sell? - MarketBeat
Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer - The Manila Times
Septerna Brings in Gil Labrucherie as Finance Chief - MarketWatch
Septerna appoints new CFO to bolster financial strategy - Investing.com
Septerna Names Biotech Veteran Gil Labrucherie as CFO, Brings $1.5B Capital Raising Success - StockTitan
Septerna (NASDAQ:SEPN) Trading 7.7% HigherShould You Buy? - MarketBeat
Septerna initiated with an Overweight at JPMorgan - MSN
Septerna (NASDAQ:SEPN) Shares Down 5%Time to Sell? - MarketBeat
Septerna (NASDAQ:SEPN) Sets New 52-Week High – Should You Buy? - Defense World
Septerna (NASDAQ:SEPN) Trading Up 8.4%Time to Buy? - MarketBeat
Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Septerna to Present GPCR Drug Discovery Pipeline at J.P. Morgan Healthcare Conference 2025 - StockTitan
Vertex Global reports ten IPOs, acquisitions worldwide in 2024 - Tech in Asia
Septerna, Inc.’s (NASDAQ:SEPN) Quiet Period Set To Expire on December 4th - Defense World
New MRGPRX2 antagonists disclosed in Septurna patent - BioWorld Online
Cantor Fitzgerald Weighs in on Septerna FY2024 Earnings - Defense World
Analysts Offer Predictions for Septerna FY2024 Earnings - MarketBeat
Septerna, Inc. Reports Q3 2024 Financials and Progress - Yahoo Finance
Septerna (NASDAQ:SEPN) Coverage Initiated at Wells Fargo & Company - Defense World
Cantor Fitzgerald Begins Coverage on Septerna (NASDAQ:SEPN) - Defense World
Septerna (NASDAQ:SEPN) Coverage Initiated at TD Cowen - Defense World
Septerna started by J.P. Morgan at overweight, GPCR platform cited - MSN
Septerna Inc. (SEPN) reports earnings - Quartz
Septerna proposes terms for upsized $175M IPO - MSN
Septerna Shares Fall 7% After Wider 3Q Loss - MarketWatch
Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Manila Times
Septerna Advances Key Drug Trial, Reports $137.5M Cash Position After Successful IPO | SEPN Stock News - StockTitan
Cantor launches Septerna stock coverage, highlighting platform value and growth in GPCR drug development - Investing.com Nigeria
TD Cowen optimistic on Septerna stock as preclinical data fuels confidence - Investing.com Canada
JPMorgan bullish on Septerna stock—pipeline strategy drives optimism - Investing.com India
Septerna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones - AOL
Septerna started by J.P. Morgan at overweight, GPCR platform cited (NASDAQ:SEPN) - Seeking Alpha
This Apollo Global Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Septerna (NASDAQ:SEPN) Coverage Initiated at Cantor Fitzgerald - MarketBeat
Septerna (NASDAQ:SEPN) Now Covered by TD Cowen - MarketBeat
Septerna (NASDAQ:SEPN) Earns Overweight Rating from Analysts at JPMorgan Chase & Co. - MarketBeat
Septerna (NASDAQ:SEPN) Earns Overweight Rating from Analysts at Wells Fargo & Company - MarketBeat
JPMorgan bullish on Septerna stock—pipeline strategy drives optimism By Investing.com - Investing.com Canada
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):